Skip to main content
OpenTrials
Completed

NCT Number: NCT06054945

Clinical Impact of IPACK Block Addition to Suprainguinal Fascia Iliaca Block

In our clinic, routine suprainguinal fascia iliaca block (SIFIB) has been administered for postoperative analgesia in patients undergoing knee arthroplasty. Recently, we have introduced the IPACK (Infiltration between the Popliteal Artery and Capsule of the Knee) block to this regimen, and the aim of this retrospective study is to determine whether the addition of the IPACK block enhances the quality of analgesia.

Knee arthroplasty, also known as knee joint replacement surgery, is a common procedure performed to alleviate pain and improve joint function in patients with knee osteoarthritis or other knee-related conditions. Postoperative pain management is crucial for patient comfort and overall recovery.

In this study, we aimed to compare the two techniques mentioned earlier, namely the SIFIB (Suprainguinal Fascia Iliaca Block) and the SIFIB+IPACK, by examining the data of patients who underwent knee arthroplasty under spinal anesthesia at our clinic between January 1, 2023, and September 1, 2023.

Completed

Looking for future studies?

Notify Me

Key information

Age range

18 year–75 year

Sex eligibility

All sexes

Study type

Observational

Primary location

Samsun University

Samsun, Turkey (Türkiye)

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Patients meeting the following criteria and whose postoperative follow-up forms were completed in full were included in the study
  • Patients underwent total knee arthroplasty (TKA)
  • ASA class I to III.
  • operated under spinal anesthesia
  • patient controlled analjgesia device was used for analgesia

Exclusion criteria

Patients whose data were inaccessible or had incomplete follow-up forms were excluded from the study to ensure the accuracy and reliability of our analysis.

  • PCA device problems in follow up in 24 hours
  • anesthesia plans were converted to general anesthesia
  • spinal anesthesia failure
  • peripheral blocks used other than protocol

Treatment and study plan

SIFIB (suprainguinal fascia iliaca block)

Procedure

Ultrasound guided Suprainguinal Fascia Iliaca Block for Knee Arthroplasty Patients

IPACK (Interspace between the popliteal artery and capsule of the posterior knee )

Other

Ultrasound guided IPACK (Interspace between the popliteal artery and capsule of the posterior knee ) Block for Knee Arthroplasty Patients

Patient controlled anagesia device

Device

Those who were administered opioids with PCA as rescue analgesic in the postoperative analgesia plan on the selected dates will be included in the study.

Other names: PCA

Primary outcomes

  1. Opioid consumption

    Time frame: 24 hours

    Opioid consumption via PCA device

Secondary outcomes

  1. NRS scores

    Time frame: 24 hours

    NRS scores in different time frames. In a Numerical Rating Scale (NRS), patients are asked to circle the number between 0 and 10, that fits best to their pain intensity. Zero usually represents 'no pain at all' whereas the upper limit represents 'the worst pain ever possible'.

Sponsors and collaborators

Lead sponsor

Samsun University

Other

Registry information

Official study title

Clinical Impact of IPACK Block Addition to Suprainguinal Fascia Iliaca Block in Knee Arthroplasty Patients Under Spinal Anesthesia: A Retrospective Cohort Study

Important dates

Study start
2023
Primary completion
2023
Study completion
2023
First posted
Sep 26, 2023
Registry last updated
Sep 29, 2023

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.